HC Wainwright Issues Pessimistic Outlook for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at HC Wainwright decreased their Q2 2025 earnings estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, May 6th. HC Wainwright analyst J. Pantginis now anticipates that the biopharmaceutical company will earn ($0.19) per share for the quarter, down from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.17 EPS.

A number of other research firms also recently weighed in on ESPR. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. The Goldman Sachs Group cut their target price on Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Finally, Needham & Company LLC dropped their price target on Esperion Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average price target of $6.25.

Esperion Therapeutics Stock Down 10.6 %

Shares of Esperion Therapeutics stock opened at $0.80 on Friday. The company has a 50-day simple moving average of $1.24 and a two-hundred day simple moving average of $1.88. Esperion Therapeutics has a twelve month low of $0.73 and a twelve month high of $3.94. The stock has a market capitalization of $158.16 million, a price-to-earnings ratio of -1.25 and a beta of 0.75.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $65.00 million during the quarter, compared to analyst estimates of $54.97 million.

Institutional Trading of Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Cibc World Markets Corp acquired a new position in Esperion Therapeutics during the fourth quarter worth about $39,000. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $55,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth $63,000. SLT Holdings LLC bought a new position in shares of Esperion Therapeutics in the 4th quarter valued at $66,000. Finally, Foundations Investment Advisors LLC grew its position in Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 9,872 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.